Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuraminidase (N2) is a tetrameric surface glycoprotein enzyme (EC 3.2.1.18) of influenza A virus, consisting of four ~470-amino-acid monomers with cytoplasmic tail, transmembrane, stalk, and catalytic head domains. It cleaves α-ketosidic linkages of terminal N-acetylneuraminic acid (sialic acid) from glycans, aiding virus entry by clearing respiratory mucins, promoting membrane fusion, and enabling efficient release of progeny virions from host cells by preventing HA-mediated aggregation. The active site features a conserved inner shell of eight residues (e.g., Arg118, Arg152, Glu276, Tyr406 using N2 numbering) for sialic acid binding and catalysis, plus framework residues for structure. N2 belongs to group 2 NA subtypes with specific activity toward α2-3 and α2-6 sialyl linkages, varying by host and isolate. It is a validated antiviral target with inhibitors binding the active site.
Competitive inhibition of sialic acid cleavage by mimicking transition state of hydrolysis, Binding to active site residues blocking substrate access
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuraminidase (N2) of influenza A virus (N2).